We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Biohit's GastroPanel Blood Test Accurately Diagnoses Hp Infection and AG Before Endoscopy

By LabMedica International staff writers
Posted on 09 May 2022
Print article
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)

Helicobacter pylori (Hp) infection, atrophic gastritis (AG) and high acid output are important risk factors for gastric and esophageal cancers. Now, the latest study to evaluate the diagnostic accuracy of a unique blood test for the diagnosis of both AG and Hp infection in patients referred for gastroscopy from primary care with different indications has confirmed its high accuracy.

Biohit Oyj’s (Helsinki, Finland) new generation GastroPanel test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach. The new generation (unified) GastroPanel test works on the same principle as the original GastroPanel ELISA test and is designed to harmonize the ELISA processing conditions of four biomarkers.

The highly informative GastroPanel assay is a cost-effective solution for population-based screening for the risk of gastric cancer in asymptomatic and symptomatic individuals, and its efficacy has already been confirmed by several studies in both high- and low-risk countries. Along with the previously published clinical validation studies, the latest biopsy-confirmed study was designed to verify the diagnostic capabilities of the new generation GastroPanel test compared to the current gold standard (gastroscopy and biopsy analysis), and to demonstrate its performance was comparable to the original GastroPanel test. The positive results from the study pave the way for BIOHIT’s new GastroPanel Quick Test (point of care test) which will be launched in Q1 2022.

“A total of 522 patients referred for gastroscopy at the Gastro Centre, OUH, were consented and enrolled for this particular study,” said Dr. Olli-Pekka Koivurova, Principal Investigator of the study. "Blood was sampled for all patients using the GastroPanel test, along with performing quality-controlled gastroscopies with mucosal biopsies. The results confirmed that the new generation GastroPanel is a highly accurate test for the non-invasive diagnosis of AG and Hp infection in patients referred for diagnostic gastroscopies.”

Related Links:
Biohit Oyj

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.